surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Read now: The SURPASS-EARLY trial

Altogether, these important findings may pave the way to developing novel antiviral strategies for treating infectious liver disease

Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, et al

Medspa settings should still maintain written protocols for injectables, devices, and emergency procedures to document training and safety oversight

Thirdly, the action of GIP on -cells has a tachyphylaxis effect

Protocol: Started at 0.5mg weekly (weeks 1-2), increased to 1mg weekly (weeks 3+)

DSIP promotes delta wave activity during deep sleep stages, enhancing the most restorative phase of sleep where physical recovery, immune function, and memory consolidation occur optimally